{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:58Z","timestamp":1787021038297,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020771","name":"Natural Science Foundation for Young Scientists of Shanxi Province","doi-asserted-by":"publisher","award":["82200855"],"award-info":[{"award-number":["82200855"]}],"id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Benign prostatic hyperplasia (BPH) is a prevalent condition characterized by nonmalignant proliferation of epithelial and stromal components in the prostate, frequently resulting in lower urinary tract symptoms in aging men. While receptor tyrosine kinase (RTK) signaling has been implicated in both benign proliferative disorders and malignant tumors, its role in BPH remains insufficiently defined. In this study, transcriptomic analyses of bulk and single-cell RNA sequencing data revealed consistent activation of RTK signaling in prostatic epithelial cells from BPH tissues. Pharmacological inhibition of this pathway using sunitinib suppressed epithelial proliferation in BPH cell lines, organoid models, and an androgen-induced BPH mouse model. Through target screening, colony-stimulating factor 1 receptor (CSF1R) was identified as a central mediator within the RTK signaling cascade. Functional experiments demonstrated that CSF1R promotes epithelial proliferation through activation of the PI3K\/AKT\/mTOR pathway. Mechanistic studies further showed that fibroblasts, which are expanded in BPH tissues, secrete CSF1 and IL34, both ligands of CSF1R, thereby enhancing downstream signaling and stimulating epithelial growth. Neutralization of these ligands or silencing of CSF1R reversed fibroblast-induced epithelial proliferation and clonogenicity. Clinical observations in patients treated with sunitinib confirmed a significant reduction in prostate volume and improvement in BPH-related urinary symptoms. Collectively, these findings establish a fibroblast\/CSF1R\/RTK signaling axis that contributes to BPH pathogenesis and support the potential of RTK inhibition as a therapeutic strategy.<\/jats:p>","DOI":"10.1186\/s43556-025-00360-w","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:13:36Z","timestamp":1764314016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fibroblasts promote the progression of benign prostatic hyperplasia through colony-stimulating factor 1 receptor-mediated RTK signaling in prostatic epithelial cells"],"prefix":"10.1186","volume":"6","author":[{"given":"Ming","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pupwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Takehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-9314","authenticated-orcid":false,"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"11","key":"360_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41585-023-00774-7","volume":"20","author":"S Gharbieh","year":"2023","unstructured":"Gharbieh S, Reeves F, Challacombe B. The prostatic middle lobe: clinical significance, presentation and management. Nat Rev Urol. 2023;20(11):645\u201353. https:\/\/doi.org\/10.1038\/s41585-023-00774-7.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"360_CR2","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"Collaborators GBDBPH","year":"2022","unstructured":"Collaborators GBDBPH. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022;3(11):e754\u201376. https:\/\/doi.org\/10.1016\/S2666-7568(22)00213-6.","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"360_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000003698.","journal-title":"J Urol"},{"issue":"4","key":"360_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.eururo.2024.04.031","volume":"86","author":"M Creta","year":"2024","unstructured":"Creta M, Russo GI, Bhojani N, Drake MJ, Gratzke C, Peyronnet B, et al. Bladder outlet obstruction relief and symptom improvement following medical and surgical therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review. Eur Urol. 2024;86(4):315\u201326. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.031.","journal-title":"Eur Urol"},{"issue":"1","key":"360_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0092-8674(01)00422-6","volume":"106","author":"HD Madhani","year":"2001","unstructured":"Madhani HD. Accounting for specificity in receptor tyrosine kinase signaling. Cell. 2001;106(1):9\u201311. https:\/\/doi.org\/10.1016\/s0092-8674(01)00422-6.","journal-title":"Cell"},{"issue":"6","key":"360_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3277","volume":"12","author":"JB Casaletto","year":"2012","unstructured":"Casaletto JB, McClatchey AI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer. 2012;12(6):387\u2013400. https:\/\/doi.org\/10.1038\/nrc3277.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"360_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-023-00161-z","volume":"5","author":"M Tao","year":"2024","unstructured":"Tao M, Shi Y, Chen H, Li J, Wang Y, Ma X, et al. The disruptor of telomeric silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases. Mol Biomed. 2024;5(1):3. https:\/\/doi.org\/10.1186\/s43556-023-00161-z.","journal-title":"Mol Biomed"},{"issue":"1","key":"360_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. https:\/\/doi.org\/10.1186\/s12943-018-0782-4.","journal-title":"Mol Cancer"},{"issue":"1","key":"360_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-021-00051-2","volume":"2","author":"A Bollig-Fischer","year":"2021","unstructured":"Bollig-Fischer A, Bao B, Manning M, Dyson G, Michelhaugh SK, Mittal S, et al. Role of novel cancer gene SLITRK3 to activate NTRK3 in squamous cell lung cancer. Mol Biomed. 2021;2(1):26. https:\/\/doi.org\/10.1186\/s43556-021-00051-2.","journal-title":"Mol Biomed"},{"issue":"1","key":"360_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00331-1","volume":"6","author":"Y Sun","year":"2025","unstructured":"Sun Y, Xu L, Deng C, Du X, Yu Y, Hao Y, et al. Distinct survival, optimal combination strategy of immunotherapy, and immunophenotype in uncommon and 20ins EGFR-mut lung adenocarcinoma: a multi-center study. Mol Biomed. 2025;6(1):88. https:\/\/doi.org\/10.1186\/s43556-025-00331-1.","journal-title":"Mol Biomed"},{"issue":"1","key":"360_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 2024;9(1):201. https:\/\/doi.org\/10.1038\/s41392-024-01899-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"360_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnves.2024.100001","volume":"1","author":"C Zeng","year":"2025","unstructured":"Zeng C. Advances in cancer treatment: the role of new technologies and research. Cell Investigation. 2025;1(1):100001. https:\/\/doi.org\/10.1016\/j.clnves.2024.100001.","journal-title":"Cell Investigation"},{"issue":"1","key":"360_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00184-0","volume":"5","author":"Y Xue","year":"2024","unstructured":"Xue Y, Ruan Y, Wang Y, Xiao P, Xu J. Signaling pathways in liver cancer: pathogenesis and targeted therapy. Mol Biomed. 2024;5(1):20. https:\/\/doi.org\/10.1186\/s43556-024-00184-0.","journal-title":"Mol Biomed"},{"key":"360_CR14","doi-asserted-by":"publisher","unstructured":"Brooks MB. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-alpha mediated inflammatory diseases. Oncologist. 2013;18(1):e3\u20135. https:\/\/doi.org\/10.1634\/theoncologist.2012-0219.","DOI":"10.1634\/theoncologist.2012-0219"},{"issue":"4","key":"360_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2006.08.021","volume":"10","author":"Z Guo","year":"2006","unstructured":"Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10(4):309\u201319. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.021.","journal-title":"Cancer Cell"},{"issue":"12","key":"360_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/jjco\/hyt145","volume":"43","author":"T Hatano","year":"2013","unstructured":"Hatano T, Ishii G, Endo K, Kishimoto K, Egawa S. Shrinkage of prostate volume in sunitinib-treated patients with renal cell carcinoma. Jpn J Clin Oncol. 2013;43(12):1282\u20135. https:\/\/doi.org\/10.1093\/jjco\/hyt145.","journal-title":"Jpn J Clin Oncol"},{"issue":"14","key":"360_CR17","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/pros.22500","volume":"72","author":"M Imura","year":"2012","unstructured":"Imura M, Kojima Y, Kubota Y, Hamakawa T, Yasui T, Sasaki S, et al. Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia. Prostate. 2012;72(14):1506\u201313. https:\/\/doi.org\/10.1002\/pros.22500.","journal-title":"Prostate"},{"issue":"1","key":"360_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00251-0","volume":"6","author":"Y Lu","year":"2025","unstructured":"Lu Y, Huang Y, Zhu C, Li Z, Zhang B, Sheng H, et al. Cancer brain metastasis: molecular mechanisms and therapeutic strategies. Mol Biomed. 2025;6(1):12. https:\/\/doi.org\/10.1186\/s43556-025-00251-0.","journal-title":"Mol Biomed"},{"issue":"1","key":"360_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01494-6","volume":"16","author":"D Huang","year":"2023","unstructured":"Huang D, Ma N, Li X, Gou Y, Duan Y, Liu B, et al. Advances in single-cell RNA sequencing and its applications in cancer research. J Hematol Oncol. 2023;16(1):98. https:\/\/doi.org\/10.1186\/s13045-023-01494-6.","journal-title":"J Hematol Oncol"},{"key":"360_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156288","volume":"169","author":"H Xu","year":"2025","unstructured":"Xu H, Gao D, Shen Y, Wang J, Wang J, Zhu J, et al. Targeting RBP4-STRA6 retinol signaling disrupts adipose-prostate crosstalk: a novel strategy to suppress basal cell plasticity in androgen deprivation. Metabolism. 2025;169:156288. https:\/\/doi.org\/10.1016\/j.metabol.2025.156288.","journal-title":"Metabolism"},{"issue":"6490","key":"360_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1126\/science.aay0267","volume":"368","author":"WR Karthaus","year":"2020","unstructured":"Karthaus WR, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, et al. Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science. 2020;368(6490):497\u2013505. https:\/\/doi.org\/10.1126\/science.aay0267.","journal-title":"Science"},{"issue":"2","key":"360_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/path.5751","volume":"255","author":"DB Joseph","year":"2021","unstructured":"Joseph DB, Henry GH, Malewska A, Reese JC, Mauck RJ, Gahan JC, et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J Pathol. 2021;255(2):141\u201354. https:\/\/doi.org\/10.1002\/path.5751.","journal-title":"J Pathol"},{"key":"360_CR23","doi-asserted-by":"publisher","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023;41(7):1345\u201362 e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.016.","DOI":"10.1016\/j.ccell.2023.05.016"},{"issue":"9","key":"360_CR24","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.18632\/aging.103175","volume":"12","author":"H Xiao","year":"2020","unstructured":"Xiao H, Jiang Y, He W, Xu D, Chen P, Liu D, et al. Identification and functional activity of matrix-remodeling associated 5 (MXRA5) in benign hyperplastic prostate. Aging (Albany NY). 2020;12(9):8605\u201321. https:\/\/doi.org\/10.18632\/aging.103175.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"360_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15913-6","volume":"11","author":"D Liu","year":"2020","unstructured":"Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987. https:\/\/doi.org\/10.1038\/s41467-020-15913-6.","journal-title":"Nat Commun"},{"key":"360_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103298","volume":"75","author":"M Zhan","year":"2024","unstructured":"Zhan M, Xu H, Yu G, Chen Q, Yang R, Chen Y, et al. Androgen receptor deficiency-induced TUG1 in suppressing ferroptosis to promote benign prostatic hyperplasia through the miR-188-3p\/GPX4 signal pathway. Redox Biol. 2024;75:103298. https:\/\/doi.org\/10.1016\/j.redox.2024.103298.","journal-title":"Redox Biol"},{"issue":"3","key":"360_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1078-0432.CCR-19-1486","volume":"26","author":"C Murga-Zamalloa","year":"2020","unstructured":"Murga-Zamalloa C, Rolland DCM, Polk A, Wolfe A, Dewar H, Chowdhury P, et al. Colony-stimulating factor 1 receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-cell lymphoma viability. Clin Cancer Res. 2020;26(3):690\u2013703. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1486.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"360_CR28","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.7150\/thno.50683","volume":"11","author":"J Munoz-Garcia","year":"2021","unstructured":"Munoz-Garcia J, Cochonneau D, Teletchea S, Moranton E, Lanoe D, Brion R, et al. The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis. Theranostics. 2021;11(4):1568\u201393. https:\/\/doi.org\/10.7150\/thno.50683.","journal-title":"Theranostics"},{"issue":"1","key":"360_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-024-01582-w","volume":"24","author":"Z Ye","year":"2024","unstructured":"Ye Z, Wang J, Xiao Y, Luo J, Xu L, Chen Z. Global burden of benign prostatic hyperplasia in males aged 60\u201390 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urol. 2024;24(1):193. https:\/\/doi.org\/10.1186\/s12894-024-01582-w.","journal-title":"BMC Urol"},{"key":"360_CR30","doi-asserted-by":"publisher","unstructured":"Bauer SR, Walter LC, Ensrud KE, Suskind AM, Newman JC, Ricke WA, et al. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA Netw Open. 2021;4(11):e2134427. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.34427.","DOI":"10.1001\/jamanetworkopen.2021.34427"},{"issue":"1","key":"360_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.juro.2013.12.053","volume":"192","author":"A Rambachan","year":"2014","unstructured":"Rambachan A, Matulewicz RS, Pilecki M, Kim JY, Kundu SD. Predictors of readmission following outpatient urological surgery. J Urol. 2014;192(1):183\u20138. https:\/\/doi.org\/10.1016\/j.juro.2013.12.053.","journal-title":"J Urol"},{"issue":"1","key":"360_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00202-1","volume":"5","author":"Y Rong","year":"2024","unstructured":"Rong Y, Ning Y, Zhu J, Feng P, Zhu W, Zhao X, et al. Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model. Mol Biomed. 2024;5(1):39. https:\/\/doi.org\/10.1186\/s43556-024-00202-1.","journal-title":"Mol Biomed"},{"key":"360_CR33","doi-asserted-by":"publisher","unstructured":"Cohen P, Cross D, Janne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551\u201369. https:\/\/doi.org\/10.1038\/s41573-021-00195-4.","DOI":"10.1038\/s41573-021-00195-4"},{"issue":"7","key":"360_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41585-023-00747-w","volume":"20","author":"K Nolla","year":"2023","unstructured":"Nolla K, Benjamin DJ, Cella D. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. Nat Rev Urol. 2023;20(7):420\u201333. https:\/\/doi.org\/10.1038\/s41585-023-00747-w.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"360_CR35","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1172\/JCI96060","volume":"128","author":"R Singh","year":"2018","unstructured":"Singh R, Karri D, Shen H, Shao J, Dasgupta S, Huang S, et al. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest. 2018;128(7):3129\u201343. https:\/\/doi.org\/10.1172\/JCI96060.","journal-title":"J Clin Invest"},{"issue":"8","key":"360_CR36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","volume":"119","author":"DA Hume","year":"2012","unstructured":"Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119(8):1810\u201320. https:\/\/doi.org\/10.1182\/blood-2011-09-379214.","journal-title":"Blood"},{"issue":"6","key":"360_CR37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","volume":"75","author":"J Escamilla","year":"2015","unstructured":"Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015;75(6):950\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0992.","journal-title":"Cancer Res"},{"issue":"1","key":"360_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00233-8","volume":"5","author":"K Lv","year":"2024","unstructured":"Lv K, He T. Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets. Mol Biomed. 2024;5(1):70. https:\/\/doi.org\/10.1186\/s43556-024-00233-8.","journal-title":"Mol Biomed"},{"key":"360_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044004","author":"SA Antar","year":"2023","unstructured":"Antar SA, Ashour NA, Marawan ME, Al-Karmalawy AA. Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24044004.","journal-title":"Int J Mol Sci"},{"key":"360_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176479","author":"AS Pollack","year":"2024","unstructured":"Pollack AS, Kunder CA, Brazer N, Shen Z, Varma S, West RB, et al. Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.176479.","journal-title":"JCI Insight"},{"issue":"7","key":"360_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0744-1","volume":"9","author":"J Sheng","year":"2018","unstructured":"Sheng J, Yang Y, Cui Y, He S, Wang L, Liu L, et al. M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death Dis. 2018;9(7):755. https:\/\/doi.org\/10.1038\/s41419-018-0744-1.","journal-title":"Cell Death Dis"},{"issue":"1","key":"360_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01644-4","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Li J, Zhou L, Wang Z, Jin L, Cao J, et al. Aberrant activation of TGF-\u03b2\/ROCK1 enhances stemness during prostatic stromal hyperplasia. Cell Commun Signal. 2024;22(1):257. https:\/\/doi.org\/10.1186\/s12964-024-01644-4.","journal-title":"Cell Commun Signal"},{"key":"360_CR43","doi-asserted-by":"publisher","unstructured":"Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010;2010(10):CD006015. https:\/\/doi.org\/10.1002\/14651858.CD006015.pub3.","DOI":"10.1002\/14651858.CD006015.pub3"},{"issue":"1","key":"360_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00216-9","volume":"5","author":"S Shan","year":"2024","unstructured":"Shan S, Su M, Wang H, Guo F, Li Y, Zhou Y, et al. Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting \u03b2-catenin pathway. Mol Biomed. 2024;5(1):52. https:\/\/doi.org\/10.1186\/s43556-024-00216-9.","journal-title":"Mol Biomed"},{"issue":"4","key":"360_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnves.2025.100035","volume":"1","author":"Q Song","year":"2025","unstructured":"Song Q, Chaudagar K, Zhang X, Waller EK. T cell-macrophage crosstalk in GVHD and cancer immunotherapy. Cell Invest. 2025;1(4):100035. https:\/\/doi.org\/10.1016\/j.clnves.2025.100035.","journal-title":"Cell Invest"},{"issue":"1","key":"360_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6.","journal-title":"Nat Commun"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00360-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:13:37Z","timestamp":1764314017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00360-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00360-w","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Ethics Committee of Shanghai Ninth People\u2019s Hospital (SH9H-2021-TK369-1), Ruijin Hospital (RJ2025038-2), and Shanghai Cancer Center (2406298\u201321). Written informed consent was obtained from all patients during hospitalization. All animal experiments were conducted in accordance with protocols approved by the Animal Experimentation Ethics Committee of the same institution, affiliated with Shanghai Jiao Tong University School of Medicine (SH9H-2021-A744-SB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}